According to the Complaint, GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions.

This action stems from a proposed transaction announced on March 7, 2019, pursuant to which GTx will merge with Oncternal Therapeutics, Inc.

On April 8, 2019, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on June 12, 2019. A related case continues under Docket 19-CV-04103 in the Southern District of New York. On August 16, the Court issued an Order consolidating cases and appointing Lead Plaintiffs and Counsel. Lead Plaintiffs filed an amended Complaint on September 23. Defendants filed a Motion to Dismiss the amended Complaint on January 10, 2020. On June 23, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiffs were given leave to amend the Complaint. On July 22, Lead Plaintiffs filed a notice appealing the Court's Dismissal Order. Lead Plaintiffs filed a stipulation withdrawing their appeal on September 30. Plaintiffs did not amend the Complaint, and on April 12, 2021, the case was dismissed with prejudice.